InMed Pharmaceuticals (INM) Cash from Investing Activities (2019 - 2024)
InMed Pharmaceuticals' (INM) quarterly Cash from Investing Activities came in at -$2.0 in Q1 2024, up 100.0% year-on-year from -$1.0 in Q2 2023, and up 99.99% quarter-over-quarter from -$33606.0 in Q2 2023.
InMed Pharmaceuticals (INM) Cash from Investing Activities (2019 - 2024) Analysis & Trends
InMed Pharmaceuticals' Cash from Investing Activities history runs 6 years deep, the most recent figure standing at -$2.0 for Q1 2024.
- On a quarterly basis, Cash from Investing Activities rose 100.0% year-over-year to -$2.0 in Q1 2024; TTM through Jun 2024 was -$161806.0, a 81.84% increase from a year earlier, with the FY2024 full-year figure at -$9293.0, up 98.6% from the prior year.
- Cash from Investing Activities improved to -$2.0 in Q1 2024 per INM's latest filing, from -$33606.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $306011.0 in Q4 2021 and bottomed at -$725457.0 in Q2 2022.
- The 5-year median for Cash from Investing Activities is -$8800.0 (2020), against an average of -$93631.9.
- Across the five-year window, Cash from Investing Activities plunged 3508.16% in 2023 and jumped 100.0% in 2024, its largest moves.
- Year by year, Cash from Investing Activities stood at $918.0 in 2020, then soared by 33234.53% to $306011.0 in 2021, then slumped by 337.07% to -$725457.0 in 2022, then surged by 95.37% to -$33606.0 in 2023, then surged by 99.99% to -$2.0 in 2024.
- Per Business Quant, the three latest INM Cash from Investing Activities figures stand at -$2.0 (Q1 2024), -$33606.0 (Q2 2023), and -$128198.0 (Q1 2023).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -60.00 Mn |
| 10 | InMed Pharmaceuticals | 6.80 Mn | 1.56 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -2.00 |
| Mar 31, 2024 | -2.00 |
| Jun 30, 2023 | -33,606.00 |
| Jun 30, 2023 | -33,606.00 |
| Mar 31, 2023 | -128,198.00 |
| Mar 31, 2023 | -128,198.00 |
| Jun 30, 2022 | -725,457.00 |
| Jun 30, 2022 | -725,457.00 |
| Mar 31, 2022 | -3,553.00 |
| Mar 31, 2022 | -3,553.00 |
| Dec 31, 2021 | 306,011.00 |
| Dec 31, 2021 | 306,011.00 |
| Sep 30, 2021 | -250,000.00 |
| Sep 30, 2021 | -250,000.00 |
| Jun 30, 2020 | 918.00 |
| Jun 30, 2020 | 918.00 |
| Mar 31, 2020 | -8,800.00 |
| Mar 31, 2020 | -8,800.00 |
| Dec 31, 2019 | 54,912.00 |
| Dec 31, 2019 | 54,912.00 |